ECSP088514A - Método para tratar danos en las articulaciones - Google Patents

Método para tratar danos en las articulaciones

Info

Publication number
ECSP088514A
ECSP088514A EC2008008514A ECSP088514A ECSP088514A EC SP088514 A ECSP088514 A EC SP088514A EC 2008008514 A EC2008008514 A EC 2008008514A EC SP088514 A ECSP088514 A EC SP088514A EC SP088514 A ECSP088514 A EC SP088514A
Authority
EC
Ecuador
Prior art keywords
damns
articulations
treat
methods
subject
Prior art date
Application number
EC2008008514A
Other languages
English (en)
Inventor
Mark Totoritis
Timothy Mark Shaw
Sunil Agarwal
David Yocum
Ariella Kelman
Original Assignee
Hoffmann La Roche
Genentech Inc
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37807774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088514(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche, Genentech Inc, Biogen Idec Inc filed Critical Hoffmann La Roche
Publication of ECSP088514A publication Critical patent/ECSP088514A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan unos métodos para tratar daños en las articulaciones en un sujeto elegible para el tratamiento, que involucran administrar un antagonista que se une a un marcador de superficie de célula B, tal como el anticuerpo CD20, al sujeto en una cantidad efectiva para retardar la progresión del daño en la articulación, según lo medido por radiografía. Se proporcionan adicionalmente unos artículos de elaboración útiles para tales métodos
EC2008008514A 2005-11-15 2008-06-09 Método para tratar danos en las articulaciones ECSP088514A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73729105P 2005-11-15 2005-11-15
US86446306P 2006-11-06 2006-11-06

Publications (1)

Publication Number Publication Date
ECSP088514A true ECSP088514A (es) 2008-10-31

Family

ID=37807774

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008514A ECSP088514A (es) 2005-11-15 2008-06-09 Método para tratar danos en las articulaciones

Country Status (29)

Country Link
US (5) US20090238762A1 (es)
EP (1) EP1951304B1 (es)
JP (4) JP2009515979A (es)
KR (5) KR20080105025A (es)
CN (2) CN101365487B (es)
AR (1) AR058838A1 (es)
AU (1) AU2006315498B2 (es)
BR (1) BRPI0618577A8 (es)
CA (2) CA2627886C (es)
CR (1) CR10005A (es)
DK (1) DK1951304T3 (es)
EC (1) ECSP088514A (es)
ES (1) ES2526616T3 (es)
HR (1) HRP20150018T1 (es)
IL (1) IL191118B (es)
MA (1) MA30047B1 (es)
MX (1) MX2008006113A (es)
MY (2) MY149159A (es)
NO (1) NO20082658L (es)
NZ (1) NZ567709A (es)
PL (1) PL1951304T3 (es)
PT (1) PT1951304E (es)
RS (1) RS53767B1 (es)
RU (1) RU2457860C2 (es)
SI (1) SI1951304T1 (es)
TW (1) TWI380826B (es)
UA (1) UA94726C2 (es)
WO (1) WO2007059188A1 (es)
ZA (1) ZA200804288B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE311199T1 (de) 1999-05-07 2005-12-15 Genentech Inc Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden
HK1043320A1 (zh) 1999-06-01 2002-09-13 Biogen, Inc. Vla-1的一种阻塞性单系抗体，以及其治疗炎性失调的功用
UA83791C2 (ru) 2001-04-13 2008-08-26 Байоджен Айдек Ма Инк. Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1
SI1613350T1 (sl) * 2003-04-09 2009-08-31 Genentech Inc Zdravljenje avtoimunske bolezni pri bolniku z neustreznim odzivom na inhibitor TNF-alfa
PT1692182E (pt) 2003-11-05 2010-05-13 Roche Glycart Ag Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
BRPI0712607A8 (pt) * 2006-05-25 2019-06-04 Biogen Idec Inc métodos de tratamento de acidente vascular cerebral
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
AU2013202392B2 (en) * 2006-12-20 2016-02-25 Mmrglobal, Inc. Antibodies and methods for making and using them
CA2673725C (en) * 2006-12-20 2016-01-12 Mmr Information Systems, Inc. Antibodies and methods for making and using them
GB0718684D0 (en) * 2007-09-24 2007-10-31 Roche Products Ltd Treatment method
US8637021B2 (en) 2007-11-12 2014-01-28 Ares Trading S.A. Formulations for TACI-immunoglobulin fusion proteins
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US9753994B2 (en) * 2009-06-19 2017-09-05 Optuminsight, Inc. System and method for generation of attribute driven temporal clustering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
RU2665954C1 (ru) 2010-10-08 2018-09-05 Новартис Аг Способы лечения псориаза с использованием антагонистов il-17
TWI616204B (zh) 2010-11-05 2018-03-01 諾華公司 Ｉｌ-１７抗體用於製備治療牛皮癬性關節炎之藥物之用途
EP2670438A4 (en) * 2011-02-03 2015-05-20 Santarus Inc SELECTION AND TREATMENT OF PATIENTS
ES2732243T3 (es) 2012-02-16 2019-11-21 Santarus Inc Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)
US20150044296A1 (en) * 2012-03-21 2015-02-12 Leonard B. Miller Combination therapy to improve joint, tendon, and ligament healing
JP2016511747A (ja) 2013-01-04 2016-04-21 マサチューセッツ インスティテュート オブ テクノロジー ナノ粒子表面結合に基づく薬物の組織への送達
JP6815196B2 (ja) 2013-03-13 2021-01-20 イマジナブ、 インコーポレイテッド Ｃｄ８に対する抗原結合性構築物
JP6486368B2 (ja) 2013-09-06 2019-03-20 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
AU2015267045B2 (en) 2014-05-27 2021-02-25 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
KR20170003720A (ko) 2014-05-27 2017-01-09 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
DK3149045T3 (da) 2014-05-27 2023-03-06 Academia Sinica Sammensætninger og fremgangsmåder vedrørende universelle glycoformer til forbedret antistofeffekt
JP7063538B2 (ja) 2014-05-28 2022-05-09 アカデミア シニカ 抗ＴＮＦα糖操作抗体群およびその使用
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CN107592812A (zh) * 2015-05-11 2018-01-16 豪夫迈·罗氏有限公司 治疗狼疮性肾炎的组合物和方法
AU2017316663B2 (en) 2016-08-22 2024-02-22 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
RU2724469C2 (ru) 2018-10-31 2020-06-23 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с cd20
PT3773558T (pt) 2019-05-10 2022-09-13 Synact Pharma Aps Tratamento combinado de doença artrítica
CA3155108A1 (en) 2019-09-20 2021-03-25 Novartis Ag Methods of treating autoimmune diseases using interleukin-17 (il-17) antagonists
EP4069086A4 (en) * 2019-12-05 2024-07-03 Imaginab, Inc. IMAGING METHODS USING MULTIPLE IMAGING AGENTS
RU2749852C1 (ru) * 2020-06-25 2021-06-17 федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Западный государственный медицинский университет им. И.И. Мечникова" Министерства здравоохранения Российской Федерации Способ лечения пациентов после травматических повреждений вращательной манжеты плечевого сустава
CN112669929B (zh) * 2020-12-30 2021-08-03 深圳大学 克罗恩病英夫利昔单抗药效预测方法及终端设备
RU2748130C1 (ru) * 2021-01-19 2021-05-19 Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр реабилитации и курортологии» Министерства здравоохранения Российской Федерации (ФГБУ «НМИЦ РК» Минздрава России) Способ отбора пациентов для экстраполяционной роботизированной механотерапии при повреждениях вращательной манжеты плеча
AU2022296767A1 (en) 2021-06-21 2024-02-01 Synact Pharma Aps Phenyl pyrrole aminoguanidine salts and formulations
EP4433506A1 (en) 2021-11-16 2024-09-25 Genentech, Inc. Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
TW202519194A (zh) * 2023-11-03 2025-05-16 台灣微脂體股份有限公司 用於疼痛控制之關節內皮質類固醇的微脂體組成物

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5506126A (en) 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
WO1989008114A1 (en) 1988-02-25 1989-09-08 The General Hospital Corporation Rapid immunoselection cloning method
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
US4861579A (en) 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DK0552142T3 (da) 1989-07-19 1998-09-07 Connetics Corp T-cellereceptorpeptider og terapeutika til autoimmune og maligne sygdomme
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
DE69322860T2 (de) 1992-04-03 1999-07-01 Genentech, Inc., South San Francisco, Calif. Antikörper gegen alpha v beta 3 integrin
ATE179329T1 (de) * 1992-06-30 1999-05-15 Procter & Gamble Pharma Arzneimitteln zur behandlung von arthritis die phosphonate und nsaids enthalten
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5417972A (en) 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
CA2150546C (en) 1993-10-21 2004-11-09 Takahide Matsuda Agent for inhibiting production of interleukin-8
AU3272695A (en) 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
ATE267610T1 (de) 1996-03-20 2004-06-15 Immunomedics Inc Glykosylierte igg antikörper
US20010056066A1 (en) 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
DK0939804T4 (da) 1996-10-25 2011-07-18 Human Genome Sciences Inc Neutrokin-alpha
WO1998027114A2 (en) 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
CA2293829C (en) 1997-06-24 2011-06-14 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
WO1999002567A2 (en) 1997-07-08 1999-01-21 Board Of Regents, The University Of Texas System Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
IL134480A0 (en) 1997-09-12 2001-04-30 Apotech Sa Kay - an immune system protein and dna sequences encoding the same
DE69840412D1 (de) 1997-10-31 2009-02-12 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
AU2093499A (en) 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
PL195870B1 (pl) 1998-08-11 2007-11-30 Biogen Idec Inc Zastosowanie przeciwciała anty-CD20, zastosowanieznakowanego radioaktywnie przeciwciała anty-CD20,zastosowanie przeciwciała anty-CD20 do przygotowania leku zwierającego przeciwciało i chemioterapięoraz zastosowanie przeciwciała anty-CD20 do przygotowania leku zawierającego przeciwciało i szpik kostny
DE19836659A1 (de) 1998-08-13 2000-02-17 Hoechst Schering Agrevo Gmbh Herbizide Mittel für tolerante oder resistente Baumwollkulturen
US6196979B1 (en) 1998-08-24 2001-03-06 Burstein Technologies, Inc. Cassette and applicator for biological and chemical sample collection
US7029652B2 (en) * 1998-09-16 2006-04-18 The Regents Of The University Of California Method of treating tumors
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
DK1616572T3 (da) 1998-11-09 2010-12-06 Biogen Idec Inc Kimært anti-CD20-antistof, rituxan, til anvendelse i behandling af kronisk lymfatisk leukæmi
HK1041811A1 (zh) 1998-11-09 2002-07-26 Idec药物公司 接受bmt或pbsc移植患者的抗cd20嵌合抗体治疗
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
GB9828074D0 (en) 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
TR200101998T2 (tr) 1999-01-07 2002-06-21 Zymogenetics, Inc. Çözünür reseptör BR 43x2 ve kullanım metodları
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
EP1035172A3 (en) 1999-03-12 2002-11-27 Fuji Photo Film Co., Ltd. Azomethine compound and oily magenta ink
US6565927B1 (en) 1999-04-07 2003-05-20 Board Of Trustees Of Michigan State University Method for treatment of surfaces with ultraviolet light
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
AU4986700A (en) 1999-05-06 2000-11-21 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
ATE311199T1 (de) * 1999-05-07 2005-12-15 Genentech Inc Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden
EP1194167B1 (en) 1999-06-09 2009-08-19 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
ITMI991299A1 (it) 1999-06-11 2000-12-11 Consiglio Nazionale Ricerche Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
DE19930748C2 (de) 1999-07-02 2001-05-17 Infineon Technologies Ag Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip
AU778863B2 (en) 1999-07-12 2004-12-23 Genentech Inc. Blocking immune response to a foreign antigen using an antagonist which binds to CD20
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US6451284B1 (en) 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
CA2378646A1 (en) 1999-08-11 2001-02-15 Idec Pharmaceuticals Corporation Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies
PL211786B1 (pl) 1999-08-17 2012-06-29 Apoxis Sa Zastosowanie przeciwciała oraz polipeptydu
AU6929100A (en) 1999-08-23 2001-03-19 Biocrystal Limited Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
US20020028178A1 (en) 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
CA2390412A1 (en) 1999-11-08 2001-05-17 Idec Pharmaceuticals Corporation Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy
EP1259595B1 (en) 2000-02-25 2007-04-04 Immunex Corporation Integrin antagonists
US20030185796A1 (en) 2000-03-24 2003-10-02 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
JP2003528155A (ja) 2000-03-24 2003-09-24 カイロン コーポレイション Ｃｄ２０に対する抗体とインターロイキン−２との組み合わせを用いる非ホジキンリンパ腫の治療方法
CN1981868A (zh) 2000-03-31 2007-06-20 拜奥根Idec公司 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
DE60130910T2 (de) 2000-04-17 2008-07-10 Ucb Pharma, S.A. Enamin-derivate als zell-adhäsionsmoleküle
EP1286692A4 (en) 2000-04-25 2004-11-17 Idec Pharma Corp INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR THE TREATMENT OF LYMPHOMAS OF THE CENTRAL NERVOUS SYSTEM
AU6836301A (en) 2000-06-20 2002-01-02 Idec Pharma Corp Treatment of b-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
WO2001097843A2 (en) 2000-06-22 2001-12-27 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
US20020058029A1 (en) 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
JP4895067B2 (ja) 2000-09-29 2012-03-14 味の素株式会社 新規フェニルアラニン誘導体
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US20020128448A1 (en) 2000-10-20 2002-09-12 Idec Pharmaceuticals Corporation Variant IgG3 Rituxan and therapeutic use thereof
KR20100031769A (ko) 2000-12-28 2010-03-24 알투스 파마슈티컬스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CN101684158A (zh) 2001-01-17 2010-03-31 特鲁比昂药品公司 结合域-免疫球蛋白融合蛋白
KR20030091978A (ko) 2001-01-29 2003-12-03 아이덱 파마슈티칼즈 코포레이션 변형된 항체 및 사용 방법
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20030103971A1 (en) 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
AU2002307037B2 (en) 2001-04-02 2008-08-07 Biogen Idec Inc. Recombinant antibodies coexpressed with GnTIII
ES2364816T3 (es) 2001-04-02 2011-09-14 Genentech, Inc. Terapia de combinación.
WO2003061694A1 (en) 2001-05-10 2003-07-31 Seattle Genetics, Inc. Immunosuppression of the humoral immune response by anti-cd20 antibodies
HU229910B1 (hu) 2001-05-11 2014-12-29 Amgen Inc Thousand Oaks A TALL-1-hez kötõdõ peptidek és rokon molekulák
WO2002102312A2 (en) 2001-06-14 2002-12-27 Intermune, Inc. Combination therapy of gamma-interferon and b cell specific antibodies
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
JP4164871B2 (ja) 2001-07-26 2008-10-15 味の素株式会社 新規フェニルプロピオン酸誘導体
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CA2453995A1 (en) 2001-08-03 2003-02-20 Genentech, Inc. Tacis and br3 polypeptides and uses thereof
ATE443259T1 (de) 2001-09-20 2009-10-15 Univ Texas Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests
GB2380127A (en) 2001-09-26 2003-04-02 Isis Innovation Treatment of chronic joint inflammation
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
EP1463524A4 (en) 2001-12-07 2005-02-09 Chiron Corp THERAPEUTIC METHODS FOR TREATING NON-HODGKINIAN LYMPHOMA
WO2003053926A1 (en) 2001-12-13 2003-07-03 Ajinomoto Co.,Inc. Novel phenylalanine derivative
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AU2003208839A1 (en) 2002-02-13 2003-09-04 Micromet Ag De-immunized (poly)peptide constructs
RU2004127458A (ru) 2002-02-14 2005-10-27 Иммуномедикс, Инк. (Us) Анти-cd20 антитела, их гибридные белки и способы их использования
EP1477482B1 (en) 2002-02-20 2010-04-14 Ajinomoto Co., Inc. Novel phenylalanine derivative
DE60334364D1 (de) 2002-02-21 2010-11-11 Univ California Behandlungsverfahren unter verwendung von anti-cd22-antikörpern
US20030180292A1 (en) 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
AU2003236020B2 (en) 2002-04-09 2009-03-19 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
EP1502603A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM
AU2003235256A1 (en) 2002-04-19 2003-11-03 Kyowa Hakko Kogyo Co., Ltd. Phenylalanine derivative
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
US20030219818A1 (en) 2002-05-10 2003-11-27 Bohen Sean P. Methods and compositions for determining neoplastic disease responsiveness to antibody therapy
EP1575514A2 (en) 2002-07-31 2005-09-21 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
KR20110017020A (ko) 2002-10-17 2011-02-18 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
SI1613350T1 (sl) * 2003-04-09 2009-08-31 Genentech Inc Zdravljenje avtoimunske bolezni pri bolniku z neustreznim odzivom na inhibitor TNF-alfa
BRPI0409420A (pt) 2003-04-18 2006-04-25 Merck Patent Gmbh pigmentos antimicrobianos
KR101351122B1 (ko) 2003-05-09 2014-01-14 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
ATE359556T1 (de) 2003-07-02 2007-05-15 Seiko Epson Corp Eine datenübertragungsvorrichtung zur übertragung von flüssigkeitsausstossdaten und eine flüssigkeitsausstossvorrichtung
US20050079184A1 (en) 2003-08-08 2005-04-14 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
PT1692182E (pt) 2003-11-05 2010-05-13 Roche Glycart Ag Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
US20050186206A1 (en) * 2003-12-19 2005-08-25 Genentech, Inc. Detection of CD20 in therapy of autoimmune diseases
EP1706424B1 (en) 2004-01-12 2009-07-22 Applied Molecular Evolution, Inc. Fc region variants
WO2005103081A2 (en) * 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US7630892B2 (en) 2004-09-10 2009-12-08 Microsoft Corporation Method and apparatus for transducer-based text normalization and inverse text normalization
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
DK2155169T3 (en) 2007-06-08 2016-06-13 Boehringer Ingelheim Int Formulation of nevirapine extended release

Also Published As

Publication number Publication date
KR20180056797A (ko) 2018-05-29
CA2783210C (en) 2016-10-04
IL191118A0 (en) 2008-12-29
PT1951304E (pt) 2015-01-02
IL191118B (en) 2018-08-30
JP2009515979A (ja) 2009-04-16
WO2007059188A1 (en) 2007-05-24
MY162988A (en) 2017-07-31
MA30047B1 (fr) 2008-12-01
MY149159A (en) 2013-07-31
SI1951304T1 (sl) 2015-02-27
HK1123209A1 (en) 2009-06-12
CN101365487A (zh) 2009-02-11
CA2627886A1 (en) 2007-05-24
KR20080105025A (ko) 2008-12-03
RS53767B1 (sr) 2015-06-30
US20190382501A1 (en) 2019-12-19
PL1951304T3 (pl) 2015-03-31
US20160176974A1 (en) 2016-06-23
KR20150105493A (ko) 2015-09-16
JP2014218518A (ja) 2014-11-20
CN103212070A (zh) 2013-07-24
BRPI0618577A8 (pt) 2016-12-20
ZA200804288B (en) 2010-10-27
RU2457860C2 (ru) 2012-08-10
AU2006315498A1 (en) 2007-05-24
DK1951304T3 (en) 2014-11-24
NO20082658L (no) 2008-08-15
KR20190009425A (ko) 2019-01-28
EP1951304A1 (en) 2008-08-06
RU2008123794A (ru) 2009-12-27
US20090238762A1 (en) 2009-09-24
AU2006315498B2 (en) 2012-08-16
TW200735889A (en) 2007-10-01
HRP20150018T1 (hr) 2015-03-27
EP1951304B1 (en) 2014-10-22
JP6132443B2 (ja) 2017-05-24
ES2526616T3 (es) 2015-01-13
KR20140099927A (ko) 2014-08-13
US20190270824A1 (en) 2019-09-05
UA94726C2 (ru) 2011-06-10
AR058838A1 (es) 2008-02-27
US10654940B2 (en) 2020-05-19
JP2013056945A (ja) 2013-03-28
CN101365487B (zh) 2013-04-17
TWI380826B (zh) 2013-01-01
US10450379B2 (en) 2019-10-22
HK1128004A1 (en) 2009-10-16
NZ567709A (en) 2011-07-29
JP2017039775A (ja) 2017-02-23
MX2008006113A (es) 2008-05-31
CR10005A (es) 2008-09-22
CA2627886C (en) 2019-01-08
US20210024643A1 (en) 2021-01-28
CA2783210A1 (en) 2007-05-24
BRPI0618577A2 (pt) 2011-09-06

Similar Documents

Publication Publication Date Title
CR10005A (es) Método para tratar daños en las articulaciones
CY1123470T1 (el) Αναστολεις ιβατ για την αγωγη ηπατοπαθειων
CO6781506A2 (es) Uso del agonista de receptor tipo toll para el tratamiento del cáncer
CL2012003110A1 (es) Compuestos derivados de n-[(2-oxo-1,2-dihidro-3-piridinil)metil]-1h-indol-4-carboxamida, inhibidores de ezh2; composicion farmaceutica que los contiene; utiles en el tratamiento del cancer seleccionado del grupo que consiste de cerebro (gliomas) glioblastomas, leucemias y linfomas, y trastornos mediados por la inhibicion del ezh2.
MX2013008376A (es) Composiciones y metodos para el tratamiento de cancer.
EA201692285A1 (ru) Ингибиторы ezh2 для лечения лимфомы
UY33480A (es) Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento.
MX2019006362A (es) Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer.
CO6341574A2 (es) Composiciones de antagonistas dl pd-1 y metodos de uso
BRPI0907135B8 (pt) uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
CL2017002283A1 (es) Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014)
ECSP13013021A (es) Compuestos de benzotiazol y su uso farmacéutico
MX2017010773A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte progamada 1 (pd-l1) para el tratamiento de cancer.
MX2012004035A (es) Anticuerpos neutralizantes anti-ngf humanos como inhibidores selectivos de la trayectoria ngf.
EP2569434A4 (en) COMPOSITIONS AND METHODS OF TREATING LEUKEMIA
CL2014000032A1 (es) Compuestos derivados de bencilamina, inhibidores de calicreina plasmatica; composicion farmaceutica; y su uso para el tratamiento de agudeza visual deteriorada, retinopatia diabetica, edema macular diabetico, hipotension cardiomiopatia, cancer, entre otros
GT201400111A (es) Triazolopiridinas sustituidas
PE20141018A1 (es) Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del sintoma tumores de celulas b
EA201591786A1 (ru) Монотерапия gla для применения в лечении рака
BR112014012607A2 (pt) métodos de tratamento usando um inibidor de interferon gama
EA202091676A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
CY1120877T1 (el) Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
MX365321B (es) Métodos para el tratamiento de neutropenia mediante agonistas retinoides.